DME Refractory Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About DME Refractory
Diabetic Macular Edema (DME) can severely impact vision, but when it becomes 'refractory,' it means standard treatments aren't working. This persistent condition requires advanced, often costly, therapies to prevent permanent vision loss. TheDrugClub understands this challenge, offering significant savings on essential prescriptions, helping you afford the care you need to protect your sight and manage this condition effectively.
Diabetic Macular Edema (DME) is a serious eye condition that can develop in people with diabetes. It occurs when high blood sugar levels damage blood vessels in the retina, leading to fluid leakage and swelling in the macula – the part of the eye responsible for sharp, central vision. This swelling can blur vision, make reading difficult, and, if left untreated, lead to permanent vision impairment or blindness.
While many people with DME respond well to initial treatments, some individuals experience what is known as 'refractory DME.' This means their macular edema persists or recurs despite receiving multiple rounds of standard therapies, typically anti-VEGF injections. When DME becomes refractory, it poses a significant challenge for both patients and healthcare providers, requiring a re-evaluation of the treatment strategy to preserve vision.
Common Treatments for Refractory DME
Initial treatment for DME often involves anti-VEGF (vascular endothelial growth factor) injections, such as Lucentis (ranibizumab), E
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.